JPM Jun 2025 280.000 call
- PR Newswire
J.P. Morgan Life Sciences Private Capital Closes Inaugural Biotechnology Venture Capital Fund with over $500 million in Commitments
J.P. Morgan Private Capital, a venture capital and growth equity investment team within J.P. Morgan Asset Management, today announced the final close of the first Life Sciences Private Capital offering, 270 Life Sciences Private Capital Fund I (the "Fund"), led by Chief Investment Officer Stephen Squinto, Ph.D. and Managing Partner Gaurav Gupta, M.D., M.S.E. The fund closed above its $500 million target, attracting strong support from investors, including institutional allocators, strategic corp
- Bloomberg
JPMorgan to Wager on Weight-Loss Boom With $500 Million Fund
(Bloomberg) -- JPMorgan Chase & Co.’s asset-management arm raised more than $500 million for a biotech venture-capital fund that will bet on the hottest corner of health care: weight-loss drugs. Most Read from BloombergWells Fargo Fires Over a Dozen for ‘Simulation of Keyboard Activity’Apple to ‘Pay’ OpenAI for ChatGPT Through Distribution, Not CashHunter Biden Was Convicted. His Dad’s Reaction Was Remarkable.US Producer Prices Surprise With Biggest Decline Since OctoberGavin Newsom Wants to Cur
- Simply Wall St.
Possible Bearish Signals With JPMorgan Chase Insiders Disposing Stock
In the last year, many JPMorgan Chase & Co. ( NYSE:JPM ) insiders sold a substantial stake in the company which may...
